NGEN News

NervGen Pharma Announces Voluntary Delisting from TSX Venture Exchange

NervGen Pharma Announces Voluntary Delisting from TSX Venture Exchange

NervGen Pharma Announces Voluntary Delisting from TSX Venture Exchange

NervGen Pharma Appoints Shamim Ruff as Chief Regulatory Affairs Officer and Christine McSherry as SVP, Patient Advocacy and Clinical Affairs

NervGen Pharma Appoints Shamim Ruff as Chief Regulatory Affairs Officer and Christine McSherry as SVP, Patient Advocacy and Clinical Affairs

NervGen Pharma to Participate at Upcoming Investor Conferences

NervGen Pharma Announces Retirement of Chief Financial Officer, Bill Adams

NervGen Pharma to Present at Unite2Fight Paralysis’ 20th Annual Science and Advocacy Symposium

NervGen Pharma Appoints Adam Rogers as Chief Executive Officer to Continue Leading the Company’s Growth and Execution of Its Mission in Spinal Cord Injury

Oncology Companion Diagnostic Research Report 2026 - Global $5+ Bn Market Trends, Opportunities, and Forecasts to 2031